A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2014

At a glance

  • Drugs Lomitapide (Primary) ; Atorvastatin; Ezetimibe; Fenofibrate
  • Indications Hyperlipidaemia
  • Focus Pharmacodynamics
  • Sponsors Aegerion Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
    • 07 Nov 2008 Interim results reported by Aegerion Pharmaceuticals in a media release.
    • 29 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top